Literature DB >> 29606501

CRISPR Gene Editing in the Kidney.

Nelly M Cruz1, Benjamin S Freedman2.   

Abstract

CRISPR is a nuclease guidance system that enables rapid and efficient gene editing of specific DNA sequences within genomes. We review applications of CRISPR for the study and treatment of kidney disease. CRISPR enables functional experiments in cell lines and model organisms to validate candidate genes arising from genetic studies. CRISPR has furthermore been used to establish the first models of genetic disease in human kidney organoids derived from pluripotent stem cells. These gene-edited organoids are providing new insight into the cellular mechanisms of polycystic kidney disease and nephrotic syndrome. CRISPR-engineered cell therapies are currently in clinical trials for cancers and immunologic syndromes, an approach that may be applicable to inflammatory conditions such as lupus nephritis. Use of CRISPR in large domestic species such as pigs raises the possibility of farming kidneys for transplantation to alleviate the shortage of donor organs. However, significant challenges remain, including how to effectively deliver CRISPR to kidneys and how to control gene editing events within the genome. Thorough testing of CRISPR in preclinical models will be critical to the safe and efficacious translation of this powerful young technology into therapies.
Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; animal model; chimeric antigen receptor T-cells (CAR-T); gene editing; gene knockout; gene therapy; genome; human pluripotent stem cells (hPSC); in vitro culture; nephrotic syndrome; organoids; polycystic kidney disease (PKD); review

Mesh:

Year:  2018        PMID: 29606501      PMCID: PMC6029248          DOI: 10.1053/j.ajkd.2018.02.347

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  79 in total

1.  Identification of genes that are associated with DNA repeats in prokaryotes.

Authors:  Ruud Jansen; Jan D A van Embden; Wim Gaastra; Leo M Schouls
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

2.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

3.  Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/β4GalNT2 genes.

Authors:  Jose L Estrada; Greg Martens; Ping Li; Andrew Adams; Kenneth A Newell; Mandy L Ford; James R Butler; Richard Sidner; Matt Tector; Joseph Tector
Journal:  Xenotransplantation       Date:  2015-03-01       Impact factor: 3.907

4.  Design of polydactyl zinc-finger proteins for unique addressing within complex genomes.

Authors:  Q Liu; D J Segal; J B Ghiara; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

5.  Correction of a pathogenic gene mutation in human embryos.

Authors:  Hong Ma; Nuria Marti-Gutierrez; Sang-Wook Park; Jun Wu; Yeonmi Lee; Keiichiro Suzuki; Amy Koski; Dongmei Ji; Tomonari Hayama; Riffat Ahmed; Hayley Darby; Crystal Van Dyken; Ying Li; Eunju Kang; A-Reum Park; Daesik Kim; Sang-Tae Kim; Jianhui Gong; Ying Gu; Xun Xu; David Battaglia; Sacha A Krieg; David M Lee; Diana H Wu; Don P Wolf; Stephen B Heitner; Juan Carlos Izpisua Belmonte; Paula Amato; Jin-Soo Kim; Sanjiv Kaul; Shoukhrat Mitalipov
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962

6.  Genome-scale CRISPR-Cas9 knockout screening in human cells.

Authors:  Ophir Shalem; Neville E Sanjana; Ella Hartenian; Xi Shi; David A Scott; Tarjei Mikkelson; Dirk Heckl; Benjamin L Ebert; David E Root; John G Doench; Feng Zhang
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

7.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

Review 8.  Modeling Kidney Disease with iPS Cells.

Authors:  Benjamin S Freedman
Journal:  Biomark Insights       Date:  2015-12-22

9.  In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa.

Authors:  Benjamin Bakondi; Wenjian Lv; Bin Lu; Melissa K Jones; Yuchun Tsai; Kevin J Kim; Rachelle Levy; Aslam Abbasi Akhtar; Joshua J Breunig; Clive N Svendsen; Shaomei Wang
Journal:  Mol Ther       Date:  2015-12-15       Impact factor: 11.454

10.  Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease.

Authors:  Nelly M Cruz; Xuewen Song; Stefan M Czerniecki; Ramila E Gulieva; Angela J Churchill; Yong Kyun Kim; Kosuke Winston; Linh M Tran; Marco A Diaz; Hongxia Fu; Laura S Finn; York Pei; Jonathan Himmelfarb; Benjamin S Freedman
Journal:  Nat Mater       Date:  2017-10-02       Impact factor: 43.841

View more
  13 in total

Review 1.  Next-Generation Sequencing-Based Genetic Diagnostic Strategies of Inherited Kidney Diseases.

Authors:  Jiahui Zhang; Changming Zhang; Erzhi Gao; Qing Zhou
Journal:  Kidney Dis (Basel)       Date:  2021-09-29

Review 2.  Emerging approaches and technologies in transplantation: the potential game changers.

Authors:  Anil Dangi; Shuangjin Yu; Xunrong Luo
Journal:  Cell Mol Immunol       Date:  2019-02-13       Impact factor: 11.530

Review 3.  Long Noncoding RNAs and Their Therapeutic Promise in Diabetic Nephropathy.

Authors:  Juan D Coellar; Jianyin Long; Farhad R Danesh
Journal:  Nephron       Date:  2021-04-14       Impact factor: 2.847

Review 4.  Modeling pancreatic pathophysiology using genome editing of adult stem cell-derived and induced pluripotent stem cell (iPSC)-derived organoids.

Authors:  Sabrina T Hirshorn; Nina Steele; Yana Zavros
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-03-24       Impact factor: 4.871

Review 5.  The Use of Genomics to Drive Kidney Disease Drug Discovery and Development.

Authors:  Dermot F Reilly; Matthew D Breyer
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-19       Impact factor: 8.237

Review 6.  Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy.

Authors:  Michail Galanopoulos; Aris Doukatas; Filippos Gkeros; Nikos Viazis; Christos Liatsos
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

7.  Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics.

Authors:  Esther Liu; Behram Radmanesh; Byungha H Chung; Benjamin S Freedman; Jennie Lin; Michael D Donnan; Dan Yi; Amal Dadi; Kelly D Smith; Jonathan Himmelfarb; Mingyao Li
Journal:  Kidney360       Date:  2020-03

8.  GDNF drives rapid tubule morphogenesis in a novel 3D in vitro model for ADPKD.

Authors:  Eryn E Dixon; Demetrios S Maxim; Victoria L Halperin Kuhns; Allison C Lane-Harris; Patricia Outeda; Andrew J Ewald; Terry J Watnick; Paul A Welling; Owen M Woodward
Journal:  J Cell Sci       Date:  2020-07-16       Impact factor: 5.285

Review 9.  Applications of kidney organoids derived from human pluripotent stem cells.

Authors:  Yong Kyun Kim; Sun Ah Nam; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2018-06-28       Impact factor: 2.884

Review 10.  Oligonucleotide-Based Therapies for Renal Diseases.

Authors:  Fernando Cartón-García; Cassondra Jeanette Saande; Daniel Meraviglia-Crivelli; Rafael Aldabe; Fernando Pastor
Journal:  Biomedicines       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.